Nuvectis Pharma Inc. Common Stock (NVCT)

FairStock Score: 10/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Nuvectis Pharma as a speculative clinical-stage biotech, not a business with an earnings record. It has no revenue in any filed period I can see. Net losses were $22.3 million in fiscal 2023, $19.0 million in fiscal 2024, and $26.4 million in fiscal 2025. In the first half of fiscal 2026, losses continued: $6.0 million in fiscal Q1 2026, the quarter ended 2026-03-31, and $7.0 million in fiscal Q2 2026, the quarter ended 2026-06-30. Trailing free cash flow is negative $19.5 million, a FairStock calculated FCF yield of -3.3%. That is the opposite of a Buffett-style cash-generating machine. The company's hope rests on NXP900, a small-molecule candidate in Phase 1b for solid tumors. With only 16 employees and no approved product, its competitive position is unproven. There is no visible moat: no pricing power, no recurring revenue, no scale. What it does have is a pipeline and, according to FairStock calculations, an Altman Z-Score of 20.12, which does not flag near-term bankruptcy risk by that measure. Still, D/E is not available and the Piotroski F-Score is 0/9. At the 2026-10-13 close of $18.15, market cap is $591.4 million. FairStock calculates P/E at -13.85, P/B at 53.38, ROE at -214.58%, and ROCE at -73.07%. Its FairStock Score is 10/100, and the Lynch category is none because it lost money in each of the last four years. Graham would ask for a margin of safety in assets or earnings; here, the price depends on future trial outcomes. I can admire the scientific effort without calling the stock a sound value investment.

In plain English: Nuvectis Pharma is a small clinical-stage drug company trying to develop a cancer medicine called NXP900; it has no product sales and has lost money in each filed period. The business looks financially weak today because it spends more than it earns, but its future depends on clinical trial results rather than current profits. At the recent close of $18.15, the stock looks expensive relative to its financial figures, though that can happen when investors are pricing in hoped-for drug success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer